|
8131 |
The Powerful Placebo Effect in Cough: Relevance to Treatment and Clinical Trials
Enthalten in Lung Bd. 198, 13.12.2019, Nr. 1, date:2.2020: 13-21
|
|
|
|
8132 |
The PRAISE study: A prospective, multi-center, randomized, double blinded, placebo-controlled study for the evaluation of iloprost in the early postoperative period after liver transplantation (ISRCTN12622749)
Enthalten in BMC surgery Bd. 13, 29.1.2013, Nr. 1, date:12.2013: 1-8
|
|
|
|
8133 |
The prebiotic effects of soluble dietary fiber mixture on renal anemia and the gut microbiota in end-stage renal disease patients on maintenance hemodialysis: a prospective, randomized, placebo-controlled study
Enthalten in Journal of translational medicine Bd. 20, 14.12.2022, Nr. 1, date:12.2022: 1-13
|
|
|
|
8134 |
The PROB-PD trial: a pilot, randomised, placebo-controlled study protocol to evaluate the feasibility and potential efficacy of probiotics in modulating peripheral immunity in subjects with Parkinson’s disease
Enthalten in Pilot and feasibility studies Bd. 9, 8.5.2023, Nr. 1, date:12.2023: 1-10
|
|
|
|
8135 |
The PROMOTe study: targeting the gut microbiome with prebiotics to overcome age-related anabolic resistance: protocol for a double-blinded, randomised, placebo-controlled trial
Enthalten in BMC geriatrics Bd. 21, 1.7.2021, Nr. 1, date:12.2021: 1-10
|
|
|
|
8136 |
The PROPHECI trial: a phase II, double-blind, placebo-controlled, randomized clinical trial for the treatment of pseudoxanthoma elasticum with oral pyrophosphate
Enthalten in Trials Bd. 26, 29.1.2025, Nr. 1, date:12.2025: 1-12
|
|
|
|
8137 |
The protocol for a multisite, double blind, randomized, placebo-controlled trial of axillary nerve stimulation for chronic shoulder pain
Enthalten in Trials Bd. 21, 6.3.2020, Nr. 1, date:12.2020: 1-10
|
|
|
|
8138 |
The protocol of the Oslo Study of Clonidine in Elderly Patients with Delirium; LUCID: a randomised placebo-controlled trial
Enthalten in BMC geriatrics Bd. 15, 10.2.2015, Nr. 1, date:12.2015: 1-14
|
|
|
|
8139 |
The Qure study: Q fever fatigue syndrome – response to treatment; a randomized placebo-controlled trial
Enthalten in BMC infectious diseases Bd. 13, 27.3.2013, Nr. 1, date:12.2013: 1-9
|
|
|
|
8140 |
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials
Enthalten in Nature Communications Bd. 15, 25.10.2024, Nr. 1, date:12.2024: 1-19
|
|
Administration
